VRTX Vertex Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRTX

Price (delayed)

$542.63

Market cap

$137.58B

P/E Ratio

34.63

Dividend/share

N/A

EPS

$15.67

Enterprise value

$139.08B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 93

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, ...

Highlights
The equity has grown by 21% YoY and by 3.3% from the previous quarter
VRTX's revenue is up by 10% YoY and by 2.9% QoQ
The EPS has declined by 10% since the previous quarter but it has increased by 10% year-on-year
Vertex Pharmaceuticals's net income has decreased by 10% QoQ but it has increased by 8% YoY
Vertex Pharmaceuticals's quick ratio has decreased by 32% QoQ and by 7% YoY
The price to earnings (P/E) is 30% more than the 5-year quarterly average of 26.8 and 19% more than the last 4 quarters average of 29.4
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vrtx.com
Peers: GILD ABBV MRK BMY

Key stats

What are the main financial stats of VRTX

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
-0.8%
1 week
0.02%
1 month
7.03%
1 year
24.98%
YTD
19.69%
QTD
3.79%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$12.95B
Gross profit
$11.08B
Operating income
$4.3B
Net income
$3.98B
Gross margin
85.5%
Net margin
30.7%
The operating margin has decreased by 12% QoQ and by 2.6% YoY
VRTX's net margin is down by 12% QoQ
VRTX's revenue is up by 10% YoY and by 2.9% QoQ
The gross profit has grown by 10% YoY and by 2.3% from the previous quarter

Price vs fundamentals

How does VRTX's price correlate with its fundamentals

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
VRTX P/E details
P/E
34.63
P/B
6.58
P/S
10.62
EV/EBIT
28.98
EV/EBITDA
27.62
EV/Sales
10.74
The price to earnings (P/E) is 30% more than the 5-year quarterly average of 26.8 and 19% more than the last 4 quarters average of 29.4
The EPS has declined by 10% since the previous quarter but it has increased by 10% year-on-year
The equity has grown by 21% YoY and by 3.3% from the previous quarter
The stock's price to book (P/B) is 9% more than its last 4 quarters average of 6.1 and 7% more than its 5-year quarterly average of 6.2
The price to sales (P/S) is 12% more than the 5-year quarterly average of 9.6 and 9% more than the last 4 quarters average of 9.8
VRTX's revenue is up by 10% YoY and by 2.9% QoQ

Efficiency

How efficient is Vertex Pharmaceuticals business performance
VRTX's return on assets is down by 16% since the previous quarter and by 9% year-on-year
The return on equity has declined by 14% since the previous quarter and by 8% year-on-year
The return on invested capital has declined by 13% since the previous quarter and by 10% year-on-year
The return on sales has declined by 12% since the previous quarter and by 2.6% year-on-year

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets is 177% higher than its total liabilities
The total liabilities has soared by 65% QoQ and by 57% YoY
Vertex Pharmaceuticals's quick ratio has decreased by 32% QoQ and by 7% YoY
VRTX's debt is 69% lower than its equity
The debt to equity has soared by 182% YoY
The equity has grown by 21% YoY and by 3.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.